Login to Your Account



CFDA approves Roche's Actemra for sJIA

By Pearl Liu
Staff Writer

Monday, December 19, 2016

HONG KONG – The CFDA approved the Roche Group's Actemra, which targets systemic juvenile idiopathic arthritis (sJIA).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription